Skip to Content

Publications Search - Abstract View

Title: Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants.
Authors: Puntervoll HE,  Yang XR,  Vetti HH,  Bachmann IM,  Avril MF,  Benfodda M,  Catricalà C,  Dalle S,  Duval-Modeste AB,  Ghiorzo P,  Grammatico P,  Harland M,  Hayward NK,  Hu HH,  Jouary T,  Martin-Denavit T,  Ozola A,  Palmer JM,  Pastorino L,  Pjanova D,  Soufir N,  Steine SJ,  Stratigos AJ,  Thomas L,  Tinat J,  Tsao H,  Veinalde R,  Tucker MA,  Bressac-de Paillerets B,  Newton-Bishop JA,  Goldstein AM,  Akslen LA,  Molven A
Journal: J Med Genet
Date: 2013 Apr
Branches: GEB, HGP, OD
PubMed ID: 23384855
PMC ID: PMC3607098
Abstract: BACKGROUND: CDKN2A and CDK4 are high risk susceptibility genes for cutaneous malignant melanoma. Melanoma families with CDKN2A germline mutations have been extensively characterised, whereas CDK4 families are rare and lack a systematic investigation of their phenotype. METHODS: All known families with CDK4 germline mutations (n=17) were recruited for the study by contacting the authors of published papers or by requests via the Melanoma Genetics Consortium (GenoMEL). Phenotypic data related to primary melanoma and pigmentation characteristics were collected. The CDK4 exon 2 and the complete coding region of the MC1R gene were sequenced. RESULTS: Eleven families carried the CDK4 R24H mutation whereas six families had the R24C mutation. The total number of subjects with verified melanoma was 103, with a median age at first melanoma diagnosis of 39 years. Forty-three (41.7%) subjects had developed multiple primary melanomas (MPM). A CDK4 mutation was found in 89 (including 62 melanoma cases) of 209 tested subjects. CDK4 positive family members (both melanoma cases and unaffected subjects) were more likely to have clinically atypical nevi than CDK4 negative family members (p<0.001). MPM subjects had a higher frequency of MC1R red hair colour variants compared with subjects with one tumour (p=0.010). CONCLUSION: Our study shows that families with CDK4 germline mutations cannot be distinguished phenotypically from CDKN2A melanoma families, which are characterised by early onset of disease, increased occurrence of clinically atypical nevi, and development of MPM. In a clinical setting, the CDK4 gene should therefore always be examined when a melanoma family tests negative for CDKN2A mutation.